Exelixis’ (EXEL) Equal Weight Rating Reiterated at Stephens

Stephens reissued their equal weight rating on shares of Exelixis (NASDAQ:EXEL) in a report published on Wednesday,Benzinga reports. The firm currently has a $29.00 price target on the biotechnology company’s stock.

EXEL has been the subject of several other reports. Brookline Capital Management began coverage on shares of Exelixis in a report on Monday, December 23rd. They issued a “buy” rating for the company. Bank of America lowered shares of Exelixis from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $35.00 to $39.00 in a report on Tuesday, December 17th. StockNews.com lowered shares of Exelixis from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Guggenheim restated a “buy” rating and issued a $42.00 price objective on shares of Exelixis in a report on Wednesday. Finally, Oppenheimer lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $41.00 to $33.00 in a report on Friday, January 24th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $37.24.

Exelixis Stock Up 1.5 %

NASDAQ:EXEL opened at $35.00 on Wednesday. The company has a fifty day moving average of $34.19 and a 200 day moving average of $30.83. Exelixis has a 52 week low of $20.14 and a 52 week high of $37.59. The firm has a market capitalization of $10.00 billion, a P/E ratio of 22.44, a P/E/G ratio of 0.63 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 22.43% and a return on equity of 20.99%. As a group, analysts anticipate that Exelixis will post 1.74 EPS for the current year.

Insider Activity at Exelixis

In other news, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the sale, the executive vice president now directly owns 486,059 shares in the company, valued at $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $35.27, for a total transaction of $352,700.00. Following the completion of the sale, the executive vice president now owns 278,665 shares of the company’s stock, valued at $9,828,514.55. This represents a 3.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 111,588 shares of company stock valued at $3,981,864. 2.85% of the stock is owned by insiders.

Institutional Trading of Exelixis

A number of large investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its position in Exelixis by 50.0% during the third quarter. GAMMA Investing LLC now owns 3,010 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 1,004 shares during the period. CWM LLC grew its position in Exelixis by 73.3% during the third quarter. CWM LLC now owns 34,643 shares of the biotechnology company’s stock valued at $899,000 after buying an additional 14,655 shares during the period. Kapitalo Investimentos Ltda bought a new stake in Exelixis during the third quarter valued at approximately $522,000. V Square Quantitative Management LLC bought a new stake in Exelixis during the third quarter valued at approximately $30,000. Finally, Inspire Advisors LLC grew its position in Exelixis by 24.9% during the third quarter. Inspire Advisors LLC now owns 25,207 shares of the biotechnology company’s stock valued at $654,000 after buying an additional 5,023 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.